Kris V Kowdley

List of Publications by Year
in descending order

136 papers	18,462 citations	28242 55 h-index	15249 126 g-index
143 all docs	143 docs citations	143 times ranked	15827 citing authors

#	Article	IF	Citations
1	IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. Hepatology, 2023, 77, 20-32.	3.6	10
2	Long‐term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States. Liver Transplantation, 2023, 29, 15-25.	1.3	2
3	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology, 2022, 76, 506-517.	1.8	49
4	Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease, 2022, 42, 379-400.	1.8	17
5	Iron overload disorders. Hepatology Communications, 2022, 6, 1842-1854.	2.0	33
6	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
7	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. Journal of Hepatology, 2021, 74, 274-282.	1.8	34
8	Investigational drugs in early phase development for primary biliary cholangitis. Expert Opinion on Investigational Drugs, 2021, 30, 131-141.	1.9	7
9	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. Hepatology Communications, 2021, 5, 786-797.	2.0	12
10	Hepcidin Signaling in Health and Disease: Ironing Out the Details. Hepatology Communications, 2021, 5, 723-735.	2.0	29
11	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications, 2021, 5, 1201-1211.	2.0	16
12	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	1.8	77
13	Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial. Hepatology, 2021, 74, 1809-1824.	3.6	163
14	Appropriate Clinical Genetic Testing of Hemochromatosis Type 2–4, Including Ferroportin Disease. The Application of Clinical Genetics, 2021, Volume 14, 353-361.	1.4	1
15	Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. Hepatology, 2021, 74, 2233-2240.	3.6	22
16	Highlights in Primary Biliary Cholangitis From the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, and the AASLD 2020 Liver Meeting Digital Experience: Commentary. Gastroenterology and Hepatology, 2021, 17, 13-15.	0.2	0
17	An Examination of the Evidence Behind Biochemical Markers in Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2021, 17, 5-11.	0.2	0
18	Rusfertide (PTG-300), a Hepcidin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemochromatosis. Blood, 2021, 138, 943-943.	0.6	1

#	Article	IF	Citations
19	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
20	Current and potential treatments for primary biliary cholangitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 306-315.	3.7	66
21	Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs, 2020, 25, 251-260.	1.0	10
22	Both Alcoholic and Nonalcoholic Steatohepatitis Is an Emerging Indication for Liver Transplantation in the United States. Digestive Disease Interventions, 2020, 04, 223-234.	0.3	0
23	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	1.8	111
24	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology, 2020, 14, 311-321.	1.4	30
25	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.2	74
26	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 2020, 72, 892-905.	3.6	227
27	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	3.6	79
28	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	6.1	28
29	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies. Liver International, 2020, 40, 2385-2393.	1.9	5
30	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
31	Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surgery and Nutrition, 2019, 8, 361-369.	0.7	12
32	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	2.8	230
33	Ombitasvir, Paritaprevir, Ritonavir, andÂDasabuvir With or Without Ribavirin inÂPatients With Kidney Disease. Kidney International Reports, 2019, 4, 245-256.	0.4	7
34	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GSâ€9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 788-801.	3.6	180
35	Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Annals of Hepatology, 2019, 18, 360-365.	0.6	6
36	Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. Journal of Leukocyte Biology, 2019, 105, 1015-1026.	1.5	112

#	Article	IF	Citations
37	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
38	Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis. Seminars in Liver Disease, 2019, 39, 209-220.	1.8	7
39	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	1.8	148
40	Serum ferritin as a biomarker for NAFLD: ready for prime time?. Hepatology International, 2019, 13, 110-112.	1.9	14
41	Efficacy and safety of ruzasvir 60Âmg and uprifosbuvir 450Âmg for 12Âweeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of Viral Hepatitis, 2019, 26, 675-684.	1.0	6
42	IDDF2019-ABS-0134â€…Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies. , 2019, , .		0
43	IDDF2019-ABS-0211â€…Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies. , 2019, , .		0
44	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. Journal of Clinical Gastroenterology, 2019, 53, 750-758.	1.1	13
45	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	6.3	818
46	ACG Clinical Guideline: Hereditary Hemochromatosis. American Journal of Gastroenterology, 2019, 114, 1202-1218.	0.2	136
47	Obeticholic acid in primary biliary cholangitis. Current Opinion in Gastroenterology, 2019, 35, 191-196.	1.0	30
48	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. American Journal of Gastroenterology, 2019, 114, 1626-1635.	0.2	65
49	Diagnosis and Management of Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 48-63.	0.2	100
50	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 156-163.e2.	2.4	322
51	Financial Compensation For Hepatologists in Different Practice Settings. Hepatology, 2019, 69, 2664-2671.	3.6	4
52	Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease. Journal of Magnetic Resonance Imaging, 2019, 49, 1456-1466.	1.9	28
53	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology, 2019, 156, 88-95.e5.	0.6	73
54	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. Journal of Hepatology, 2019, 70, 133-141.	1.8	149

#	Article	IF	Citations
55	Relationship between three commonly used nonâ€invasive fibrosis biomarkers and improvement in fibrosis stage in patients with nonâ€alcoholic steatohepatitis. Liver International, 2019, 39, 924-932.	1.9	47
56	Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World Journal of Hepatology, 2019, 11, 710-718.	0.8	10
57	Pediatric cholestatic liver disease: Successful transition of care. Cleveland Clinic Journal of Medicine, 2019, 86, 454-464.	0.6	1
58	Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed. Gastroenterology and Hepatology, 2019, 15, 669-671.	0.2	0
59	Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals. Drugs and Aging, 2018, 35, 117-122.	1.3	15
60	Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2018, 24, 269-276.	0.9	5
61	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. Clinical Gastroenterology and Hepatology, 2018, 16, 567-574.e6.	2.4	25
62	Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clinical Gastroenterology and Hepatology, 2018, 16, 417-426.	2.4	191
63	Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2018, 22, 23-37.	1.0	233
64	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
65	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	3.6	70
66	Performance characteristics of vibrationâ€controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology, 2018, 67, 134-144.	3.6	192
67	A randomized, placeboâ€controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2018, 67, 1754-1767.	3.6	528
68	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
69	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	3.6	55
70	Development and validation of a primary sclerosing cholangitisâ€“specific patientâ€reported outcomes instrument: The PSC PRO. Hepatology, 2018, 68, 155-165.	3.6	22
71	IDDF2018-ABS-0113â€...The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
72	You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. American Journal of Clinical Nutrition, 2018, 108, 1162-1163.	2.2	0

#	Article	IF	Citations
73	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12â€¯weeks in HCV DAA-experienced patients. Journal of Hepatology, 2018, 69, 1221-1230.	1.8	50
74	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1
75	Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. Blood, 2018, 132, 2336-2336.	0.6	5
76	Curcumin and Turmeric Modulate the Tumor-Promoting Effects of Iron In Vitro. Nutrition and Cancer, 2017, 69, 481-489.	0.9	13
77	Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of Hepatology, 2017, 66, 703-710.	1.8	81
78	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Advances in Nutrition, 2017, 8, 253-265.	2.9	38
79	Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology, 2017, 65, 1094-1103.	3.6	53
80	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
81	An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. Clinics in Liver Disease, 2017, 21, 709-723.	1.0	10
82	Isolation and characterization of iron chelators from turmeric (Curcuma longa): selective metal binding by curcuminoids. BioMetals, 2017, 30, 699-708.	1.8	14
83	New developments in the treatment of primary biliary cholangitis – role of obeticholic acid. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1053-1060.	0.9	34
84	Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis. Annals of Hepatology, 2017, 16, 77-85.	0.6	28
85	Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission. Indian Journal of Medical Research, 2017, 146, 1.	0.4	0
86	Update on hepatitis C treatment: systematic review of clinical trials. Minerva Gastroenterology, 2017, 63, 62-73.	0.3	2
87	Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepatic Medicine: Evidence and Research, 2016, Volume 8, 75-80.	0.9	7
88	Sofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
89	Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology, 2016, 63, 1112-1119.	3.6	67
90	Onâ€treatment <scp>HCV RNA</scp> as a predictor of sustained virological response in <scp>HCV</scp> genotype 3â€“infected patients treated with daclatasvir and sofosbuvir. Liver International, 2016, 36, 1611-1618.	1.9	20

#	Article	IF	Citations
91	The Effects of Alcohol on Other Chronic Liver Diseases. Clinics in Liver Disease, 2016, 20, 581-594.	1.0	13
92	Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients WithÂHepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gastroenterology, 2016, 151, 902-909.	0.6	52
93	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a realâ€world cohort study. Hepatology, 2016, 64, 1893-1899.	3.6	61
94	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	13.9	817
95	Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterology, 2016, 3, e000114.	1.1	21
96	Disruption of Iron Regulation after Radiation and Donor Cell Infusion. Biology of Blood and Marrow Transplantation, 2016, 22, 1173-1181.	2.0	1
97	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir andÂSofosbuvir. Gastroenterology, 2016, 151, 501-512.e1.	0.6	192
98	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	6.1	139
99	Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. American Journal of Physiology - Renal Physiology, 2016, 310, G117-G127.	1.6	109
100	Safety and efficacy of ledipasvirâ€sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology, 2016, 63, 437-444.	3.6	55
101	Acidophil bodies in nonalcoholic steatohepatitis. Human Pathology, 2016, 52, 28-37.	1.1	8
102	Hepatitis B Virusâ€“Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	0.6	178
103	The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clinics in Liver Disease, 2016, 20, 225-243.	1.0	85
104	A Proton Pump Inhibitor a Day Keeps the Iron Away. Clinical Gastroenterology and Hepatology, 2016, 14, 153-155.	2.4	7
105	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. PLoS ONE, 2016, 11, e0150195.	1.1	15
106	Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?. World Journal of Gastroenterology, 2016, 22, 6965.	1.4	18
107	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. Hepatology, 2015, 62, 1339-1341.	3.6	33
108	Glyceronephosphate Oâ€acyltransferase as a hemochromatosis modifier gene: Another iron in the fire?. Hepatology, 2015, 62, 337-339.	3.6	7

#	Article	IF	Citations
109	Treatment with ledipasvir and sofosbuvir improves patientâ€reported outcomes: Results from the IONâ€1, â€2, and â€3 clinical trials. Hepatology, 2015, 61, 1798-1808.	3.6	127
110	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	0.6	470
111	ACG Clinical Guideline: Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 646-659.	0.2	400
112	Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology, 2015, 62, 25-30.	3.6	82
113	Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology, 2015, 63, 364-369.	1.8	115
114	Management of chronic hepatitis B infection. BMJ, The, 2015, 351, h4263-h4263.	3.0	54
115	Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection. Open Forum Infectious Diseases, 2015, 2, ofv056.	0.4	9
116	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
117	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	6.3	1,840
118	1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis. Open Forum Infectious Diseases, 2014, 1, S42-S42.	0.4	0
119	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
120	Iron Deficiency in Patients With Nonalcoholic Fatty Liver Disease Is Associated With Obesity, Female Gender, and Low Serum Hepcidin. Clinical Gastroenterology and Hepatology, 2014, 12, 1170-1178.	2.4	34
121	Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. New England Journal of Medicine, 2014, 370, 1879-1888.	13.9	1,080
122	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. New England Journal of Medicine, 2014, 370, 222-232.	13.9	262
123	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. Journal of Hepatology, 2014, 61, 1238-1246.	1.8	126
124	Predicting outcome in primary biliary cirrhosis. Annals of Hepatology, 2014, 13, 316-26.	0.6	19
125	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet, The, 2013, 381, 2100-2107.	6.3	265
126	MicroRNAs in Liver Disease: Bench to Bedside. Journal of Clinical and Experimental Hepatology, 2013, 3, 231-242.	0.4	23

#	Article	IF	Citations
127	Dendritic cells in NASH: Friend or foe?. Annals of Hepatology, 2013, 12, 508-509.	0.6	5
128	Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma.. Journal of Clinical Oncology, 2013, 31, 177-177.	0.8	0
129	Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology, 2012, 56, 422-433.	3.6	342
130	Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2012, 55, 77-85.	3.6	412
131	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology, 2011, 53, 448-457.	3.6	261
132	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2010, 362, 1675-1685.	13.9	2,718
133	High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50, 808-814.	3.6	603
134	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary Clinical Trials, 2009, 30, 88-96.	0.8	140
135	The Glasgow-Blatchford Bleeding Score identified patients with upper GI bleeding who could be managed as outpatients. Annals of Internal Medicine, 2009, 150, JC5.	2.0	8
136	Reply:. Hepatology, 2008, 47, 1795-1796.	3.6	1